Technical Trend Evolution and Price Movement
The stock closed at ₹2,404.95 on 19 Jun 2026, marking a 1.75% increase from the previous close of ₹2,363.50. Intraday price action saw a high of ₹2,409.60 and a low of ₹2,363.45, reflecting a relatively tight trading range but with upward bias. The 52-week high stands at ₹2,726.75, while the 52-week low is ₹1,909.90, positioning the current price closer to the upper end of its annual range.
The technical trend has upgraded from mildly bullish to bullish, signalling stronger price momentum. This is corroborated by the daily moving averages which are firmly bullish, indicating that short-term price averages are trending higher and supporting the current price level.
MACD and Momentum Indicators
The Moving Average Convergence Divergence (MACD) indicator presents a nuanced picture. On the weekly timeframe, MACD is bullish, reflecting positive momentum and suggesting that the stock’s upward trend is gaining strength. However, on the monthly timeframe, MACD remains mildly bearish, indicating some longer-term caution. This divergence suggests that while short- to medium-term momentum is improving, longer-term investors should monitor for confirmation of sustained strength.
The Know Sure Thing (KST) indicator on the weekly chart is mildly bearish, adding a note of caution to the momentum narrative. The absence of a monthly KST reading suggests limited longer-term momentum clarity at this stage.
RSI and Overbought/Oversold Conditions
The Relative Strength Index (RSI) on both weekly and monthly timeframes currently shows no clear signal, implying the stock is neither overbought nor oversold. This neutral RSI reading supports the view that the stock has room to move higher without immediate risk of a technical pullback due to overextension.
Bollinger Bands and Volatility
Bollinger Bands readings are bullish on both weekly and monthly charts, indicating that price volatility is expanding in favour of upward movement. The stock price is likely trading near or above the upper band, a sign of strong buying interest and potential continuation of the rally.
Volume and On-Balance Volume (OBV)
On-Balance Volume (OBV) is mildly bearish on the weekly timeframe and neutral on the monthly, suggesting that volume trends are not fully confirming the price gains. This divergence between price and volume may warrant caution, as sustained rallies ideally require volume support to validate strength.
Our current Stock of the Month is out! This Large Cap from Automobiles - Passenger Cars emerged as the single best opportunity from our elite universe. Get the details now!
- - Current monthly selection
- - Single best opportunity
- - Elite universe pick
Moving Averages and Daily Price Action
The daily moving averages are bullish, reinforcing the positive short-term trend. This suggests that the stock’s recent price gains are supported by consistent buying interest and that the trend is likely to continue barring any external shocks. The alignment of moving averages typically acts as a dynamic support level, which investors can watch closely for potential entry points.
Dow Theory and Trend Confirmation
According to Dow Theory, there is no clear trend on either the weekly or monthly timeframe. This absence of a definitive trend signal implies that while technical momentum is improving, the broader market confirmation of a sustained uptrend is yet to materialise. Investors should therefore remain vigilant for further confirmation signals before committing heavily.
Comparative Returns and Market Context
Examining Mankind Pharma’s returns relative to the Sensex provides additional context. Over the past week, the stock returned 1.4%, underperforming the Sensex’s 4.85% gain. However, over the year-to-date period, Mankind Pharma has delivered a robust 9.5% return, significantly outperforming the Sensex’s negative 9.17% return. Over the last three years, the stock has surged 48.25%, more than doubling the Sensex’s 22.13% gain, highlighting its strong medium-term performance within the Pharmaceuticals & Biotechnology sector.
These returns underscore the stock’s resilience and growth potential despite short-term volatility and sector headwinds.
Want to dive deeper on Mankind Pharma Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Mojo Score and Analyst Ratings
Mankind Pharma currently holds a Mojo Score of 72.0, categorised as a Buy grade, upgraded from Hold on 18 Jun 2026. This upgrade reflects improved technical and fundamental assessments by MarketsMOJO analysts, signalling increased confidence in the stock’s near-term prospects. The mid-cap classification further emphasises the stock’s growth potential balanced with moderate risk.
Investors should note that the upgrade aligns with the technical momentum shift observed in the recent price action and indicator signals, reinforcing the bullish outlook.
Investment Implications and Outlook
The technical indicators collectively suggest that Mankind Pharma is entering a phase of stronger upward momentum. The bullish MACD on the weekly chart, supportive Bollinger Bands, and positive daily moving averages provide a compelling case for continued price appreciation. However, the mildly bearish monthly MACD and weekly KST, alongside neutral RSI and Dow Theory signals, counsel a degree of caution and the need for ongoing monitoring.
Volume trends, as indicated by the mildly bearish weekly OBV, highlight the importance of watching for sustained buying interest to confirm the rally’s strength. Investors may consider using pullbacks to moving average support levels as potential entry points, while keeping an eye on broader market and sector developments.
Given the stock’s strong medium-term returns relative to the Sensex and the recent technical upgrade, Mankind Pharma remains an attractive proposition for investors seeking exposure to the Pharmaceuticals & Biotechnology sector with a balanced risk-reward profile.
Summary
In summary, Mankind Pharma Ltd’s technical parameters have shifted favourably, signalling a bullish momentum phase. While some longer-term indicators remain cautious, the overall technical landscape supports a positive near-term outlook. The recent Mojo Grade upgrade to Buy further validates this stance, making the stock a noteworthy candidate for investors focused on mid-cap pharmaceutical growth opportunities.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
